Related Experiment Video
Updated: Feb 8, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Use of nonintrusive sensor-based information and communication technology for real-world evidence for clinical trials
Stefan Teipel1, Alexandra König2, Jesse Hoey3
1Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany; DZNE, German Center for Neurodegenerative Diseases, Rostock, Germany.
Abstract:
Cognitive function is an important end point of treatments in dementia clinical trials. Measuring cognitive function by standardized tests, however, is biased toward highly constrained environments (such as hospitals) in selected samples. Patient-powered real-world evidence using information and communication technology devices, including environmental and wearable sensors, may help to overcome these limitations. This position paper describes current and novel information and communication technology devices and algorithms to monitor behavior and function in people with prodromal and manifest stages of dementia continuously, and discusses clinical, technological, ethical, regulatory, and user-centered requirements for collecting real-world evidence in future randomized controlled trials. Challenges of data safety, quality, and privacy and regulatory requirements need to be addressed by future smart sensor technologies. When these requirements are satisfied, these technologies will provide access to truly user relevant outcomes and broader cohorts of participants than currently sampled in clinical trials.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
The Evidence for Evolution
Dementia
The progression of dementia is generally gradual....
Statistical Software for Data Analysis and Clinical Trials
Communication

